Although we did not directly assess these immune parameters, the interplay between HMGB1-mediated signaling and immune regulation represents a promising avenue for future research, particularly in the context of combination therapies targeting both tumor cells and the tumor microenvironment. The gene discussed is HMGB1; the disease is neoplasm.